Recap: Blueprint Medicines Q3 Earnings

Blueprint Medicines BPMC reported its Q3 earnings results on Tuesday, November 1, 2022 at 08:00 AM.

Here's what investors need to know about the announcement.

Earnings

Blueprint Medicines beat estimated earnings by 10.44%, reporting an EPS of $-2.23 versus an estimate of $-2.49.

Revenue was up $41.79 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.45 which was followed by a 6.06% increase in the share price the next day.

Here's a look at Blueprint Medicines's past performance:

To track all earnings releases for Blueprint Medicines visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.